Nelmastobart

耐玛苏拜单抗

Report date: 2026/03/03 15:18:19

Base Information

Drug NameNelmastobart
Drug Alias Name人源化抗BTN1A1单克隆抗体hSTC-810STT-003STC-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionButyrophilin subfamily 1 member A1 inhibitors
TargetsButyrophilin subfamily 1 member A1
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSTCube Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSTCube Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A